Free Trial

Radiopharm Theranostics (RADX) Competitors

Radiopharm Theranostics logo
$5.07 +0.36 (+7.64%)
As of 12:35 PM Eastern

RADX vs. IOBT, GLSI, ACOG, CCCC, NVCT, THTX, CLLS, SPRO, CGEN, and GNLX

Should you be buying Radiopharm Theranostics stock or one of its competitors? The main competitors of Radiopharm Theranostics include IO Biotech (IOBT), Greenwich LifeSciences (GLSI), Alpha Cognition (ACOG), C4 Therapeutics (CCCC), Nuvectis Pharma (NVCT), Theratechnologies (THTX), Cellectis (CLLS), Spero Therapeutics (SPRO), Compugen (CGEN), and Genelux (GNLX). These companies are all part of the "med - biomed/gene" industry.

Radiopharm Theranostics vs. Its Competitors

IO Biotech (NASDAQ:IOBT) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, IO Biotech had 11 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 15 mentions for IO Biotech and 4 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 0.75 beat IO Biotech's score of -0.07 indicating that Radiopharm Theranostics is being referred to more favorably in the news media.

Company Overall Sentiment
IO Biotech Neutral
Radiopharm Theranostics Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IO BiotechN/AN/A-$95.49M-$1.49-0.80
Radiopharm TheranosticsN/AN/AN/AN/AN/A

IO Biotech presently has a consensus target price of $8.67, suggesting a potential upside of 625.85%. Radiopharm Theranostics has a consensus target price of $15.00, suggesting a potential upside of 195.86%. Given IO Biotech's higher probable upside, analysts plainly believe IO Biotech is more favorable than Radiopharm Theranostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IO Biotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33
Radiopharm Theranostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
3.67

54.8% of IO Biotech shares are owned by institutional investors. 2.3% of IO Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Radiopharm Theranostics' return on equity of 0.00% beat IO Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
IO BiotechN/A -162.55% -125.08%
Radiopharm Theranostics N/A N/A N/A

Summary

IO Biotech and Radiopharm Theranostics tied by winning 5 of the 10 factors compared between the two stocks.

Get Radiopharm Theranostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RADX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RADX vs. The Competition

MetricRadiopharm TheranosticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$39.95M$3.03B$5.50B$9.81B
Dividend YieldN/A2.28%4.59%4.13%
P/E RatioN/A17.3829.9425.16
Price / SalesN/A349.44445.68102.78
Price / CashN/A40.7324.8128.01
Price / BookN/A8.988.685.82
Net IncomeN/A-$54.75M$3.26B$265.22M
7 Day Performance-3.43%-0.94%0.61%0.75%
1 Month Performance22.46%7.33%3.33%1.97%
1 Year PerformanceN/A23.30%45.75%27.33%

Radiopharm Theranostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RADX
Radiopharm Theranostics
N/A$5.07
+7.6%
$15.00
+195.9%
N/A$39.95MN/A0.00N/AGap Down
IOBT
IO Biotech
3.2497 of 5 stars
$2.23
+5.2%
$9.33
+318.5%
-25.5%$146.91MN/A-1.5030Trending News
Analyst Forecast
Gap Up
High Trading Volume
GLSI
Greenwich LifeSciences
1.8208 of 5 stars
$10.94
-2.8%
$39.00
+256.5%
-7.6%$146.27MN/A-8.683News Coverage
Positive News
Upcoming Earnings
ACOG
Alpha Cognition
1.5452 of 5 stars
$9.11
-1.8%
$20.00
+119.5%
N/A$145.94MN/A-7.59N/A
CCCC
C4 Therapeutics
2.7307 of 5 stars
$2.05
-5.1%
$12.00
+485.4%
-55.3%$145.57M$35.58M-1.39150News Coverage
Earnings Report
Analyst Downgrade
Analyst Revision
NVCT
Nuvectis Pharma
2.5181 of 5 stars
$6.96
-7.8%
$17.00
+144.3%
-9.6%$145.39MN/A-6.168News Coverage
Earnings Report
High Trading Volume
THTX
Theratechnologies
N/A$3.15
flat
N/A+131.9%$144.84M$84.38M-16.58140Positive News
CLLS
Cellectis
2.4653 of 5 stars
$2.51
-6.0%
$4.00
+59.4%
+27.4%$139.52M$47.63M-2.92290Gap Up
SPRO
Spero Therapeutics
3.8613 of 5 stars
$2.32
+6.9%
$5.00
+115.5%
+71.9%$129.71M$28.30M-1.81150
CGEN
Compugen
1.7806 of 5 stars
$1.45
+0.7%
$4.00
+175.9%
-14.3%$129.40M$27.86M-9.0670News Coverage
Earnings Report
Analyst Downgrade
Analyst Revision
Gap Down
GNLX
Genelux
1.6974 of 5 stars
$3.39
-4.0%
$17.75
+423.6%
+54.0%$128.01M$10K-3.8510Positive News
Earnings Report
Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:RADX) was last updated on 8/12/2025 by MarketBeat.com Staff
From Our Partners